Amgen and AstraZeneca have racked up their third straight Phase III win for brodalumab in plaque psoriasis, beating J&J’s Stelara in a head-to-head study. The news comes just two weeks after the pharmacy partners posted their latest positive results, positioning them for a run at regulators on both sides of the Atlantic.

There are two key scores in this study, dubbed AMAGINE-2; 100 percent skin clearance (PASI 100) and 75 percent clearance (PASI 75).

The numbers: 44.4 percent of patients in the brodalumab 210-mg group, 33.6 percent of patients in the brodalumab weight-based group, 25.7 percebtof patients in the brodalumab 140-mg group, 21.7 percent of patients in the Stelara group and 0.6 percent of patients in the placebo group achieved total clearance of skin disease (PASI 100). The showdown numbers were a bit mixed for PASI 75: 86.3 percent of patients in the brodalumab 210-mg group, 77 percent of patients in the brodalumab weight-based group, 66.6 percent of patients in the brodalumab 140-mg group, 70 percentof patients in the Stelara group and 8.1 percent of patients in the placebo group achieved PASI 75.